Edward P. Ambinder
Icahn School of Medicine at Mount Sinai
33 Papers
382 Citations
Edward P. Ambinder is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 16, co-authored 32 publications. Previous affiliations of Edward P. Ambinder include Mount Sinai Hospital & City University of New York.
Chat about Author
Papers
Electronic Health Records
TL;DR: The concept of the EHR was formulated to integrate an individual's multiple, physician-generated, electronic medical records and the patient-generated personal health record to facilitate optimal management of the health of an individual or, when used in aggregate, of a population.
Plasmapheresis in Refractory Generalized Myasthenia Gravis
Peter Kornfeld,Edward P. Ambinder,Thomas W. Mittag,Adam N. Bender,Angelos E. Papatestas,Judith D. Goldberg,Gabriel Genkins +6 more
TL;DR: A group of 16 patients with severe generalized myasthenia gravis that was resistant to anticholinesterases, thymectomy, and corticosteroids were treated by plasmapheresis and 12 patients showed an excellent clinical response.
65
Therapeutic leukapheresis for hyperleukocytosis in acute myelocytic leukemia
Janet Cuttner,Janet Cuttner,James F. Holland,Larry Norton,Edward P. Ambinder,Gail Button,Richard J. Meyer +6 more
TL;DR: Twenty-two patients with newly diagnosed acute myelocytic leukemia (AML) and white cell counts (WBC) greater than 100,000/microliters received one, two, or three leukaphereses prior to induction chemotherapy with cytosine arabinoside (Ara-C and daunorubicin (DNR).
63
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Colon and Rectum
Angela N. Bartley,Stanley R. Hamilton,Randa Alsabeh,Edward P. Ambinder,Michael A. Berman,Elaine Collins,Patrick L. Fitzgibbons,Donna M. Gress,Jan A. Nowak,Wade S. Samowitz,S. Yousuf Zafar +10 more
TL;DR: The College of American Pathologists offers these templates to assist pathologists in providing clinically useful and relevant information when reporting results of biomarker testing.
55
Protein A immunoadsorption in the treatment of malignant disease.
Gerald L. Messerschmidt,David H. Henry,Snyder Hw,Juergen H. Bertram,A. Mittelman,Ainsworth S,Fiore J,M V Viola,J Louie,Edward P. Ambinder +9 more
TL;DR: Protein A immunoadsorption of plasma is well tolerated in the outpatient clinic, has demonstrated antitumor activity in resistant solid tumors, and functions as a biologic response modifier.
52